Takeda sells $2.3B in products as it seeks to pay down Shire debt
Takeda Pharmaceutical Co. Ltd., the state's largest biotech employer, will divest $2.3 billion of its consumer business in a bid to pay down debt from its 2019 Shire acquisition.
Multiple Japanese news outlets had reported last week that Takeda (NYSE: TAK) is considering selling part of its consumer health business to private equity giant The Blackstone Group (NYSE: BX). Nikkei Asian Review listed the sale price as $2.37 billion, while the Japan Times reports it could go f or as high as $2.9 billion.
On…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
More News: Biotechnology | Health Management | Japan Health | Mergers and Aquisitions | Pharmaceuticals